Featured Research

from universities, journals, and other organizations

Lung Transplants In Cystic Fibrosis Patients With Life-threatening Bacteria Sparks Debate

Date:
April 15, 2008
Source:
International Society for Heart and Lung Transplantation
Summary:
At a recent symposium researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF. Patients with life threatening lung disease due to CF have a lot to gain by lung transplantation. Compared to other possible indications for transplant, patients with CF have, in general, the best outcomes, and a successful transplant can mean a significant increase in lifespan and a huge improvement in quality of life.

At a recent symposium* researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.

Related Articles


Patients with life threatening lung disease due to CF have a lot to gain by lung transplantation. Compared to other possible indications for transplant, patients with CF have, in general, the best outcomes, and a successful transplant can mean a significant increase in lifespan and a huge improvement in quality of life.

A hallmark of advanced CF lung disease is repeated severe chest infections. In most cases these infections are responsive to treatment with powerful antibiotics and their presence does not influence the outcomes after transplant in CF patients.

However in 5 percent of patients with CF, bacteria called Burkholderia cenocepacia infects the lungs before transplant. This infection is very resistant to antibiotics and if it returns after the transplant surgery it is extremely difficult to control and can be life threatening.

It is estimated that less than only 30 percent of patients with Burkholderia cenocepacia who receive lung transplants survive beyond five years with many dying very early after transplant due to recurrence of the severe infection with this bacteria. In comparison, CF patients without this infection can expect 5-year post-transplant survival of up to 70 percent on average. The debate within the transplant community is whether or not to allocate donor lungs to patients with Burkholderia cenocepacia knowing that the success rate is much worse than in CF patients without this infection.

According to Dr. Davis, lung transplants should not be performed on CF patients with Burkholderia cenocepacia until new research indicates a way to achieve better early results by better control of the infection. He went on to say new ways of treating patients with Burkholderia cenocepacia should be examined in clinical trials with a hypothesis, careful data collection and safety monitoring. Only after such research approaches have generated a clinical advance in treatment of this infection should lung transplants in CF patients with Burkholderia cenocepacia be performed in the same manner as those who do not have the disease.

Representing the counter argument, Dr. Souilemas said he believes it is very difficult to choose between two patients who need the same procedure. "Medicine is science and art," said Dr. Souilemas in the debate. During his argument, Dr. Souilemas also presented information on reversible factors other than the infection itself, which may contribute to the patients' poor health before receiving a lung transplant, and thus contribute to poor outcomes. Dr. Souilemas finished his debate by proposing that each patient be viewed as a potential lung transplant candidate and encouraged clinicians to attempt to transplant each as successfully as possible.

In the end, both physicians agreed that more careful research into transplants in CF patients with Burkholderia cenocepacia would improve success rates for these patients.

*During the April 9 Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.

A highlight of the session was the concluding debate: Burkholderia Cenocepacia is an Absolute Contradiction to Transplantation between Duane Davis, MD, Duke University Medical Center, Durham, NC and Redha R. Souilemas, MD, European Georges Pompidou Hospital, Paris.


Story Source:

The above story is based on materials provided by International Society for Heart and Lung Transplantation. Note: Materials may be edited for content and length.


Cite This Page:

International Society for Heart and Lung Transplantation. "Lung Transplants In Cystic Fibrosis Patients With Life-threatening Bacteria Sparks Debate." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080411150847.htm>.
International Society for Heart and Lung Transplantation. (2008, April 15). Lung Transplants In Cystic Fibrosis Patients With Life-threatening Bacteria Sparks Debate. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2008/04/080411150847.htm
International Society for Heart and Lung Transplantation. "Lung Transplants In Cystic Fibrosis Patients With Life-threatening Bacteria Sparks Debate." ScienceDaily. www.sciencedaily.com/releases/2008/04/080411150847.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins